Loading...
Loading...
Contributors:
Dataset URI:
10.3389/fonc.2026.1931817.s001BackgroundNeoadjuvant chemoimmunotherapy (nCIT) has emerged as a standard treatment for locally advanced esophageal squamous cell carcinoma (ESCC). This study aimed to evaluate the independent prognostic value of postoperative pathological N stage (ypN) and to assess whether pre-treatment clinical N stage (cN) provides additional prognostic information in patients achieving ypN0.MethodsWe retrospectively analyzed 194 ESCC patients who received nCIT followed by radical esophagectomy between January 2019 and December 2024. Patients were stratified into three groups: cN0/ypN0 (n=104), cN+/ypN0 (n=32), and ypN+ (n=58). Kaplan-Meier analysis and Cox proportional hazards models were used for survival analysis. Multivariable models were constructed using a clinically informed variable-selection strategy constrained by the number of events. For the three pairwise comparisons, unadjusted P values were compared against a Bonferroni-adjusted significance threshold of alpha=0.017 (0.05/3).ResultsA total of 194 patients were enrolled, with 31 deaths and 37 recurrences during a median follow-up of 34.0 months (reverse Kaplan–Meier). ypN+ patients had significantly worse overall survival (OS) and recurrence-free survival (RFS) than ypN- patients (both Log-rank PConclusionPostoperative ypN stage is the core prognostic determinant in ESCC after nCIT. In patients achieving ypN0, pre-treatment cN did not demonstrate statistically significant additional prognostic discrimination in this cohort, although estimates were imprecise due to the small cN+/ypN0 subgroup and limited events. Postoperative risk assessment should be based primarily on ypN status; these findings require validation in larger, preferably multicenter, cohorts.
Keyword(s):
clinical N stage; esophageal squamous cell carcinoma; neoadjuvant chemoimmunotherapy; Oncology and Carcinogenesis not elsewhere classified; pathological N stage.
MeSH Term(s):
Grants and Funding:
No Grants or Funding Data Available
Associated Publication(s):
Supplementary Data:
No Supplementary Data Available
Related Dataset(s):
No Related Dataset Data Available
The National Library of Medicine (NLM) provides information about biomedical datasets. Inclusion on an NLM Web page does not imply endorsement of, or agreement with, the contents by NLM or the National Institutes of Health. Learn more: NLM Web Policies (nih.gov)